YOLFTbeta
Molecure S.A.

Molecure S.A.

MOC · WAR · Healthcare / Biotechnology

5.52PLN+0.11 (+2.03%)

Price History

Full chart

Market Stats

Previous Close5.41
Open5.50
Day Range5.42 – 5.63
52-Week Range4.98 – 9.04
Volume34.11K
Market Cap175.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.99
Dividend Yield0.00%
Beta1.00
50-Day Avg6.58
200-Day Avg6.33

About

Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Marcin Jan Szumowski Ph.D.
  • Employees71
  • HeadquartersZwirki i Wigury 101, Warsaw, Poland, 02-089, Poland
  • Websitehttps://molecure.com

Leadership

  • Dr. Marcin Jan Szumowski Ph.D.Co-Founder, CEO & President of Management Board
  • Dr. Zbigniew ZaslonaChief Scientific Officer & Member of Management Board
  • Ms. Agnieszka Rajczuk-SzczepanskaHR Director
  • Dr. Adam Golebiowski Ph.D.Co-Founder & VP of Research Chemistry
  • Mr. Jacek Olczak Ph.D.Co-Founder & Head of Medicinal Chemistry
  • Ms. Monika CzarneckaFinance Director
  • Ms. Magdalena TyszkiewiczHead of CMC
  • Mr. Dariusz Stencel M.D., Ph.D.Chief Medical Officer

Financials

Income Statement

Currency: PLN2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue5.40K6.60K6.00K3.00K2.81K122.94M4007.51M1002.92M-
Growth (%)-+22.22%-9.09%-50.00%-6.43%+4379536.62%-100.00%+1878262.25%-100.00%+2919000.00%-
Cost of Revenue58.41K56.84K104.94K149.71K146.86K38.41M2.77M1.63M4.10M3.41M-
Gross Profit-53.01K-50.24K-98.94K-146.71K-144.06K84.53M-2.77M-21.33K-4.10M-489.91K-
Gross Margin-981.69%-761.26%-1648.93%-4890.20%-5131.99%68.76%-693272.50%-0.28%-4101610.00%-16.78%-
Operating Expense740.44K2.47M2.48M4.97M4.68M10.83M10.99M43.89M28.03M33.12M-
Operating Income-793.46K-2.52M-2.58M-5.12M-4.83M73.70M-13.76M-43.91M-32.13M-33.61M-22.04M
Operating Margin-14693.61%-38248.91%-42935.05%-170682.30%-171945.46%59.95%-3441074.75%-584.40%-32128045.00%-1151.35%-
EBITDA-477.47K-2.32M-2.31M-4.38M-3.85M73.88M-13.33M-31.85M-25.51M-27.37M-19.03M
EBITDA Margin-8842.11%-35139.05%-38460.48%-146096.67%-137134.06%60.10%-3332504.75%-423.89%-25505806.00%-937.75%-
Net Income-559.11K-2.42M-2.40M-3.78M-4.16M67.96M-13.64M-13.54M-28.37M-31.29M-15.69M
Net Income Margin-10353.81%-36731.71%-40072.20%-125905.30%-148127.18%55.28%-3410639.00%-180.21%-28373117.00%-1071.83%-
R&D309.18K1.54M-126.13K-38.31M2.59M11.63M2.72M2.36M1.29M
R&D as % of Total Revenue5725.50%23309.26%-4204.43%-31.16%647350.50%154.73%2718598.00%80.71%-
Interest Expense40.94K33.94K29.81K31.62K81.19K6.21K6.48K16.36K89.20K94.23K76.92K
Interest Expense % of Total Revenue758.20%514.18%496.80%1054.00%2892.59%0.01%1620.50%0.22%89200.00%3.23%-

Balance Sheet

Currency: PLN2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.54M16.52M15.52M34.57M86.02M85.69M153.50M151.59M138.06M112.27M113.72M94.43M
Total Liabilities560.05K1.09M2.51M4.85M4.12M6.56M10.09M10.45M11.61M11.34M10.31M6.99M
Total Equity3.98M15.43M13.01M29.72M81.89M79.13M147.09M141.14M126.45M100.93M103.41M87.45M
Cash2.29M6.69M2.53M13.20M51.86M34.04M120.50M102.04M65.62M63.99M18.19M16.35M
Total Debt-----3.83M5.23M6.01M6.41M7.14M7.23M5.29M
Net Debt-2.29M-6.69M-2.53M-13.20M-51.86M-30.21M-115.27M-96.03M-59.21M-56.85M-10.96M-11.06M

Cash Flow

Currency: PLN2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.53M-1.44M-599.63K-4.89M-7.11M57.44M-13.50M-10.21M-23.29M-56.99M-19.41M
Investing Cash Flow-12.38M-14.56M-24.00M-27.38M-34.85M8.58M-18.82M-33.59M-33.87M-23.57M-16.60M
Financing Cash Flow18.31M11.84M35.27M70.93M24.13M20.45M13.86M7.38M55.53M34.76M34.46M
Capital Expenditure12.38M14.56M24.00M27.39M34.89M2.09M18.83M33.63M362.23K23.77M3
Free Cash Flow-13.91M-16.00M-24.60M-32.28M-42.00M55.35M-32.33M-43.84M-23.65M-80.76M-19.41M
FCF to OCF908.91%1110.88%4102.94%660.20%590.85%96.37%239.55%429.29%101.56%141.72%100.00%

Earnings

Report DateSep 25, 2018Nov 29, 2018Apr 26, 2019Sep 25, 2019Nov 8, 2019Mar 30, 2020Apr 30, 2020Sep 25, 2020Oct 31, 2020Mar 31, 2021Sep 27, 2021Oct 29, 2021Mar 25, 2022Apr 29, 2022Sep 29, 2022Oct 31, 2022Mar 30, 2023Apr 27, 2023Sep 29, 2023Oct 30, 2023Mar 28, 2024Mar 31, 2024Jun 30, 2024Oct 14, 2024Mar 28, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026
EPS Estimate------------------------------
EPS Actual-0.10-0.05-0.09-0.06-0.06-0.09-0.06-0.03-0.064.79-0.20-0.13-0.49-0.23-0.27-0.16-0.42-0.23-0.29-0.25-0.40-0.41-0.63-0.37-0.52-0.26-0.17-0.26-0.08-0.20
Surprise------------------------------
TimingPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hours--After-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hours--After-hoursAfter-hours-----

Key Statistics & Ratios

Market Cap175.04M
Enterprise Value175.97M
Trailing P/E0.00
Forward P/E0.00
Price / Sales26.85
Price / Book2.16
EPS-0.99
Book Value4.34
Revenue (TTM)6.52M
Gross Profit (TTM)-16.56M
EBITDA-15.63M
Profit Margin-240.64%
Operating Margin-61.33%
Return on Equity-16.27%
Return on Assets-17.15%
Shares Outstanding24.72M
Shares Float16.30M
Beta1.00
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%